A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

oxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company0 个研究点目标入组 500 人开始时间: 2021年2月23日最近更新: 2024年8月5日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 500

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•At least 18 years of age
•Confirmed diagnosis by local laboratory of MCL with documentation of overexpression of cyclin D1 with at least one B-cell marker (e.g., CD19, CD20, or PAX5) and/or t (11;14) by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction.
•Previously treated with at least one prior line of systemic therapy for MCL.
•Measurable disease by PET-CT and / or CT / MRI as defined by Lugano criteria and aligned with protocol imaging requirements:
•- at least one nodal lesion (> 1.5 cm in long axis) or extranodal lesion (> 1.0 cm in long axis) measurable in 2 dimensions, not previously radiated (unless progression has been radiographically documented following radiation therapy).
•Documented evidence of radiographically and/or histologically confirmed PD on the most recent line of therapy or relapse prior to study enrollment.
•Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
•Adequate organ function
•Must have life expectancy of at least 3 months
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 200
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 300

排除标准

•Current suspected or confirmed active central nervous system (CNS) involvement with MCL or previous CNS involvement.
•Prior treatment with an approved or investigational BTK inhibitor.
•Major surgery within 4 weeks prior to randomization.
•History of bleeding diathesis.
•History of stroke or intracranial hemorrhage within 6 months of randomization.
•History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within 60 days of randomization.
•Significant cardiovascular disease.
•Prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec during Screening.
•Known human immunodeficiency virus (HIV) infection, regardless of CD4 count.
•Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
•Known active cytomegalovirus (CMV) infection. Unknown or negative status are eligible.
•Pregnancy during the study or within 3 months of the last dose of study treatment.
•Clinically significant active malabsorption syndrome or other condition likely to affect GI absorption of the study drug.
•Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and medical monitor may pose a risk for patient participation. Screening for chronic conditions is not required.
•History of second malignancy unless in remission for at least 2 years; in-situ carcinomas not requiring treatment intervention, non-melanoma skin cancer curatively treated, nonmetastatic breast, or nonmetastatic prostate cancer where hormonal therapy is being continued as standard of care are allowed.
•Prior/Concomitant Therapy
•Ongoing chronic treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers which cannot be stopped within 3-5- half-lives of the CYP3A inhibitor therapy prior to start of study drug treatment.
•Because of their effect on CYP3A4, use of any of the following within 3 days of study therapy start is prohibited: Grapefruit or grapefruit products, Seville oranges or products from Seville oranges, Star fruit or star fruit products.
•Steroid use with antineoplastic intent within 7 days of study drug initiation.
•Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.
•Vaccination with a live vaccine within 28 days prior to randomization.
•Have a known hypersensitivity to any of the excipients of pirtobrutinib or to the intended covalent BTK inhibitor if randomized to control arm.
•Laction, or plan to breastfeed during the study or within 2 weeks of the last dose of study treatment

研究者

发起方

oxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company

相似试验

进行中（未招募）

1 期

A Phase 3 Study Comparing LOXO-305 to Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus RituximabChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-004554-30-IEoxo Oncology Inc250

进行中（未招募）

1 期

EUCTR2020-004554-30-HRoxo Oncology Inc250

进行中（未招募）

1 期

EUCTR2020-004554-30-CZoxo Oncology Inc250

招募中

1 期

A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL 321)Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104

CTIS2023-507697-40-00oxo Oncology Inc.238

招募中

3 期

A Phase 3 Study of LOXO-305 in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

JPRN-jRCT2021210031Shahda , MD Safi10